Cheng Chunxu, Pan Weina, Li Xiang, Qu Hongyan
Department of Infectious Diseases, Changchun Hospital for Infectious Diseases, Changchun, Jilin 130031, P.R. China.
Department of Radiology, The Third People's Hospital of Gongzhuling City, Siping, Jilin 136105, P.R. China.
Exp Ther Med. 2020 Sep;20(3):2236-2244. doi: 10.3892/etm.2020.8957. Epub 2020 Jun 29.
Tuberculosis is highly infectious and has a high incidence worldwide. Therefore, effective treatment is essential for the disease. The immune function and inflammatory factors can reflect the therapeutic effect of pulmonary tuberculosis to some extent. Thus, the aim of the present study was to investigate the clinical effect of vitamin D supplementation on pulmonary tuberculosis patients and its influence on the expression of immune cells and inflammatory factors in patients. A total of 256 patients with pulmonary tuberculosis who were admitted to our hospital were collected as research participants; 120 patients who were treated with conventional antituberculosis drugs were taken as a control group (CG) and 136 patients who were treated with vitamin D-assisted antituberculosis drugs were taken as the research group (RG). The levels of inflammatory factors (IL-6, MMP-9, IL-4, TNF-α) and T lymphocyte subgroup of patients were measured in both groups before and after treatment. The efficacy was compared in both groups. The disappearance time of wheezing and cough in RG was shorter than that in CG (P<0.001). There was no difference in X-ray chest plain film, sputum examination results and efficacy of patients in both groups (P>0.05). After treatment, CD3, CD4, CD4/CD8 were upregulated in both groups (P<0.05), while CD3, CD4, CD4/CD8 in RG were higher than those in CG (P<0.05). After treatment, inflammatory factors in both groups improved compared with those before treatment. Serum inflammatory factors in RG were significantly lower than those in CG (P<0.05). After treatment, surfactant protein in the two groups was lower than that before treatment, while that in RG was significantly lower than that in CG (P<0.05). After treatment, soluble selectins in both groups improved significantly. The level of soluble selectins in RG was slightly lower than that in CG. The incidence of adverse reactions in RG was lower than that in CG. The life quality scores of patients in RG were slightly higher than those in CG (P<0.05). In conclusion, vitamin D-assisted antituberculosis drugs can effectively improve the immune function and expression level of inflammatory factors in pulmonary tuberculosis patients and reduce adverse reactions.
肺结核具有高度传染性,在全球发病率很高。因此,有效的治疗对该疾病至关重要。免疫功能和炎症因子在一定程度上可以反映肺结核的治疗效果。因此,本研究的目的是探讨补充维生素D对肺结核患者的临床疗效及其对患者免疫细胞表达和炎症因子的影响。收集我院收治的256例肺结核患者作为研究对象;将120例接受常规抗结核药物治疗的患者作为对照组(CG),将136例接受维生素D辅助抗结核药物治疗的患者作为研究组(RG)。分别检测两组患者治疗前后炎症因子(IL-6、MMP-9、IL-4、TNF-α)水平及T淋巴细胞亚群。比较两组疗效。研究组喘息和咳嗽消失时间短于对照组(P<0.001)。两组患者胸部X线平片、痰检结果及疗效比较,差异无统计学意义(P>0.05)。治疗后,两组CD3、CD4、CD4/CD8均上调(P<0.05),但研究组高于对照组(P<0.05)。治疗后,两组炎症因子较治疗前均有所改善。研究组血清炎症因子明显低于对照组(P<0.05)。治疗后,两组表面活性蛋白均低于治疗前,且研究组明显低于对照组(P<0.05)。治疗后,两组可溶性选择素均明显改善。研究组可溶性选择素水平略低于对照组。研究组不良反应发生率低于对照组。研究组患者生活质量评分略高于对照组(P<0.05)。综上所述,维生素D辅助抗结核药物可有效提高肺结核患者的免疫功能和炎症因子表达水平,减少不良反应。